MDNAF on OTC

Medicenna Therapeutics Corp.

Pharmaceutical preparations company based in Toronto, listed on OTC (MDNAF)¹

In its 2023 annual report (Form 20-F) the company says: “Medicenna Therapeutics Corp., formerly A2 Acquisition Corp., is the resulting issuer following a “three-cornered” amalgamation involving A2, 1102209 B.C. Ltd., a wholly owned subsidiary of A2 incorporated pursuant to the Business Corporations Act (British Columbia), and Medicenna Therapeutics Inc., completed on March 1, 2017.”¹¹

Price unavailable

Last updated Oct 21, 2026.

Overview

-10.0MNet income, fiscal 2023²

Compare with another stock.

TickerMDNAF on OTC¹
IndustryPharmaceutical Preparations¹
HeadquartersZ4¹
Incorporated inCanada (Federal Level)³
Business address2 Bloor Street W., Suite 903, Toronto³
Filer categoryNon-accelerated filer, Emerging growth company³
Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-34.1%Return on equity²

Financial statements

Net income⁴²-$10.0M in 2023+21% since 2020

Fiscal year	2020	2021	2022	2023
Research and development			14.7M CAD²	9.3M CAD²
Income before tax			-22.6M CAD²	-10.0M CAD²
Income tax			0 CAD²	0 CAD²
Net income	-8.3M CAD⁴	-17.3M CAD²	-22.6M CAD²	-10.0M CAD²
Earnings per share	-0 CAD/shares⁴	-0 CAD/shares²	-0 CAD/shares²	-0 CAD/shares²
Shares (weighted, basic)			54.3M shares²	64.7M shares²

Total assets⁵⁴²$36.4M in 2023−4% since 2020

Total liabilities⁵²$7.0M in 2023+277% since 2020

Shareholders’ equity⁴²$29.5M in 2023+1027% since 2019

Cash⁴²$33.6M in 2023+1317% since 2019

Fiscal year	2019	2020	2021	2022	2023
Cash	2.4M CAD⁴	22.7M CAD²	30.4M CAD²	20.5M CAD²	33.6M CAD²
Current assets				23.4M CAD²	36.4M CAD²
Intangible assets				65.0K CAD²	61.0K CAD²
Total assets		38.0M CAD⁵	42.3M CAD⁴	23.5M CAD²	36.4M CAD²
Accounts payable				2.6M CAD²	3.8M CAD²
Current liabilities				2.6M CAD²	3.8M CAD²
Total liabilities		1.8M CAD⁵	4.1M CAD⁵	2.6M CAD²	7.0M CAD²
Retained earnings				-70.9M CAD²	-81.0M CAD²
Shareholders’ equity	2.6M CAD⁴	36.1M CAD²	38.1M CAD²	20.8M CAD²	29.5M CAD²
Shares outstanding			53.5M shares⁵	55.6M shares⁴	69.6M shares²

Cash from operations⁴-$23.6M in 2022+336% since 2020

Fiscal year	2020	2021	2022
Cash from operations	-5.4M CAD⁴	-15.3M CAD⁴	-23.6M CAD⁴
Cash from investing			10.1M CAD⁴
Cash from financing			3.9M CAD⁴

Compare Medicenna Therapeutics Corp. with another company

Corporate structure

Medicenna Therapeutics Corp. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Medicenna Therapeutics Corp.

RA CAPITAL MANAGEMENT, L.P. Filed SC 13G on Medicenna Therapeutics Corp., latest May 10, 2024
Fahar Merchant Filed SC 13G/A on Medicenna Therapeutics Corp., latest Feb 21, 2024 (3 filings since Feb 10, 2022)
Orin Hirschman Filed SC 13G/A on Medicenna Therapeutics Corp., latest Feb 7, 2024 (3 filings since Oct 20, 2022)

Medicenna Therapeutics Corp. Z4

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Medicenna Therapeutics Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Operating-lease assets (leased space)	0 CAD⁴ Mar 31, 2022	32.0K CAD⁴ Mar 31, 2021	−100.0%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	33.6M CAD² Mar 31, 2023	20.5M CAD² Mar 31, 2022	+63.6%

Intangibles and goodwill

Item	Latest	A year before	Change
Intangible assets, net (excluding goodwill)	61.0K CAD² Mar 31, 2023	65.0K CAD² Mar 31, 2022	−6.2%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerDavid Hyman named May 14, 2024 to Jul 6, 2026⁶
Executive Officer, DirectorFahar Merchant named May 14, 2024 to Jul 6, 2026⁶
Executive OfficerNageatte Ibrahim named Jul 6, 2026⁶
Executive OfficerRosemina Merchant named May 14, 2024 to Jul 6, 2026⁶
DirectorAlbert G. Beraldo named May 14, 2024 to Jul 6, 2026⁶
DirectorAngelos G. Georgakis named Jul 6, 2026⁶
DirectorJohn G. Geltosky named May 14, 2024 to Jul 6, 2026⁶
DirectorKarim G. Lalji named Jul 6, 2026⁶
DirectorRichard G. Sutin named Jul 6, 2026⁶
DirectorJohn Sampson named May 14, 2024⁷
DirectorKaren Dawes named May 14, 2024⁷

Filings

123 filings to the SEC since October 2021: 2 annual reports, 7 large holders, 2 private raises, 112 other. The latest 20:

Jul 6, 2026D EDGAR
May 14, 2024D EDGAR
May 14, 202415-12G FORM 15 EDGAR
May 13, 2024EFFECT EDGAR
May 13, 20246-K EDGAR
May 10, 2024POS AM EDGAR
May 10, 2024SC 13G EDGAR
Apr 30, 20246-K EDGAR
Apr 26, 20246-K EDGAR
Apr 25, 20246-K EDGAR
Apr 22, 2024AW EDGAR
Apr 16, 2024S-8 POS EDGAR
Apr 16, 2024F-3/A EDGAR
Apr 16, 2024F-10POS EDGAR
Apr 10, 20246-K EDGAR
Apr 9, 20246-K EDGAR
Apr 4, 20246-K EDGAR
Mar 6, 20246-K EDGAR
Feb 21, 2024SC 13G/A EDGAR
Feb 14, 20246-K EDGAR

The 123 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

RA CAPITAL MANAGEMENT, L.P.SC 13G, 1 filing May 10, 2024⁸
Fahar MerchantSC 13G/A, 3 filings Feb 10, 2022 to Feb 21, 2024⁹
Orin HirschmanSC 13G/A, 3 filings Oct 20, 2022 to Feb 7, 2024¹⁰

Money raised

Private offerings the company reported to the SEC on Form D.

May 28, 2026Raised $253,458 in a private offering of equity Form D: $2.3 million offered in all Form D
Apr 30, 2024Raised $14.6 million in a private offering of equity Form D: $14.6 million offered in all Form D

SEC filer profile

How Medicenna Therapeutics Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARMedicenna Therapeutics Corp.¹
CIK0001807983
Filer statusNon-accelerated filer<br>emerging growth company¹
Incorporated inCanada (Federal Level)¹
Fiscal year endsMarch 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address2 Bloor Street W., Suite 903, Toronto, Ontario, Canada¹
Phone403-613-1453¹
Shares outstanding69,637,469 as of Mar 31, 2023²
On EDGAR sinceMar 30, 2020¹
Filings178 in all: 6-K (140), SC 13G/A (5), SUPPL (4), D (3), EFFECT (3), SC 13G (3), 20-F (2), 15-12G (1)¹
All 25 form types
25-NSE (1), 40-F (1), 8-A12B (1), AW (1), CERT (1), CORRESP (1), D/A (1), F-10 (1), F-10/A (1), F-10POS (1), F-3 (1), F-3/A (1), F-X (1), POS AM (1), S-8 (1), S-8 POS (1), UPLOAD (1)
Latest filingsAnnual report (20-F) Jun 27, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMedicenna Therapeutics Corp. filings on SEC EDGAR
2
SEC EDGARMedicenna Therapeutics Corp. 10-K for fiscal 2023
3
SEC EDGARMedicenna Therapeutics Corp. filings on SEC EDGAR
4
SEC EDGARMedicenna Therapeutics Corp. 10-K for fiscal 2020
5
SEC EDGARMedicenna Therapeutics Corp. 10-K for fiscal 2020
6
SEC EDGARMedicenna Therapeutics Corp. Form D naming David Hyman
7
SEC EDGARMedicenna Therapeutics Corp. Form D naming John Sampson
8
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SC 13G on Medicenna Therapeutics Corp.
9
SEC EDGARFahar Merchant SC 13G/A on Medicenna Therapeutics Corp.
10
SEC EDGAROrin Hirschman SC 13G/A on Medicenna Therapeutics Corp.
11
SEC EDGARMedicenna Therapeutics Corp. filing with the SEC